Pitolisant

證據等級: L5

預測適應症: 3 個

Pitolisant: From Narcolepsy to Insomnia (Signal Requires Verification)

One-Sentence Summary

Pitolisant is a histamine H3-receptor inverse agonist known from the literature for narcolepsy and OSA-related excessive daytime sleepiness — i.e., a wake-promoting drug. The TxGNN model predicts it may be effective for Insomnia, but this is supported by only 1 withdrawn trial (for an unrelated indication) and 8 publications, most of which actually describe the opposite clinical effect. This prediction shows a direct mechanistic contradiction and should be treated as a research question, not an actionable signal.

Quick Overview

Item	Content
Original Indication	Narcolepsy with/without cataplexy (per literature evidence only; no formal regulatory record in this dataset)
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.71%
Evidence Level	L4
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal drugbank MOA data is not available for this drug (data gap). Based on the literature evidence attached to this candidate, pitolisant is a selective histamine H3-receptor inverse agonist/antagonist. By blocking H3 autoreceptors, it increases histaminergic, noradrenergic, and dopaminergic tone in the brain, producing a wake-promoting effect. This mechanism is the basis for its approved use in narcolepsy (with or without cataplexy) and its investigational use for residual excessive daytime sleepiness (EDS) in OSA patients on CPAP.

This is precisely why the "insomnia" prediction is mechanistically counter-intuitive: a drug designed to increase wakefulness would be expected to worsen, not treat, insomnia. Seven of the eight literature citations attached to this indication actually describe pitolisant's use for narcolepsy or EDS in OSA — the clinical opposite of insomnia — and the single associated clinical trial (also withdrawn, zero enrollment) targeted alcohol use disorder, not sleep initiation/maintenance problems.

The most plausible explanation, consistent with the rationale already flagged in this evidence pack, is that the TxGNN knowledge graph node labeled "insomnia (disease)" may be embedding-adjacent to narcolepsy/hypersomnia/EDS disease nodes, producing a false-positive association rather than a genuine therapeutic hypothesis. This needs to be manually verified against the KG's disease ontology before any further evaluation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02800083	Phase 2	Withdrawn	0	Designed to evaluate pitolisant for alcohol use disorder (heavy drinking days as primary endpoint), not insomnia. Withdrawn with zero enrollment — no efficacy or safety data generated, and the target indication does not match the predicted one.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36931805	2023	RCT	Lancet Neurology	Phase 3 RCT of pitolisant in pediatric narcolepsy with/without cataplexy — confirms wake-promoting efficacy, not an insomnia indication.
33121980	2021	RCT	Chest	RCT in OSA patients with residual excessive daytime sleepiness despite CPAP — pitolisant used to increase wakefulness.
31917607	2020	RCT	Am J Respir Crit Care Med	RCT for daytime sleepiness in OSA patients refusing CPAP — again a wake-promoting use, clinically opposite to insomnia treatment.
36169322	2022	Cohort	Revista de Neurología	Real-world study of pitolisant in treatment-refractory type 1 narcolepsy with cataplexy.
34225942	2021	Review	Handbook of Clinical Neurology	General review of histamine receptor pharmacology (H1–H4); mechanistic background only, not indication-specific.
30214155	2018	Review	Drug Design, Development and Therapy	Review of pitolisant's development and place in therapy for narcolepsy.
34521328	2022	Review	Current Neuropharmacology	Reviews histaminergic system changes in neuropsychiatric disease; notes pitolisant is used for EDS in narcolepsy, contrasted with H1-antagonist doxepin being the drug actually used for insomnia.
22356925	2012	Review/Mechanistic	Clinical Neuropharmacology	Early mechanistic review of pitolisant as a stimulant for narcolepsy-cataplexy in teenagers.

Note: No publication in this evidence set actually studies pitolisant for insomnia treatment. Several sources explicitly describe the opposite pharmacological effect (wake-promotion).

Germany Market Information

Pitolisant is currently not marketed in this jurisdiction, and no marketing authorization records are available in the dataset.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (insomnia) is mechanistically implausible given pitolisant's well-documented wake-promoting pharmacology, and the only attached clinical trial is unrelated and withdrawn. The bulk of the literature evidence actually supports the opposite clinical use (EDS/narcolepsy), suggesting the TxGNN signal is likely a knowledge-graph artifact rather than a genuine repurposing opportunity.

To proceed, the following is needed:

Manual verification of the "insomnia (disease)" node definition and its graph neighbors in the TxGNN knowledge graph, to rule out confusion with narcolepsy/hypersomnia/EDS nodes
Formal DrugBank MOA confirmation (currently a data gap, DG002)
TFDA/BfArM label warnings and contraindications (currently a blocking data gap, DG001) before any safety-relevant evaluation
If the KG node is confirmed as true insomnia (not a mislabeled hypersomnia-adjacent node), dedicated preclinical or clinical insomnia data would be required before this candidate could be reconsidered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.